Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) is a sensitive measure of disease contro...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Avet-Loiseau, Hervé, San-Miguel, Jesus, Casneuf, Tineke, Iida, Shinsuke, Lonial, Sagar, Usmani, Saad Z., Spencer, Andrew, Moreau, Philippe, Plesner, Torben, Weisel, Katja, Ukropec, Jon, Chiu, Christopher, Trivedi, Sonali, Amin, Himal, Krevvata, Maria, Ramaswami, Priya, Qin, Xiang, Qi, Mia, Sun, Steven, Qi, Ming, Kobos, Rachel, Bahlis, Nizar J.
Format: Artigo
Langue:Inglês
Publié: Wolters Kluwer Health 2021
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078259/
https://ncbi.nlm.nih.gov/pubmed/33513030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01814
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires